Levodopa therapy is the gold standard for symptomatic treatment of Parkinson's disease (PD), but levodopa and/or dopamine (DA)-induced neurotoxicity have been reported in both in vitro and in vivo experimental studies. To clarify the beneficial effects of combining DA agonists with levodopa in PD, the present study examines the effects of cabergoline, a DA agonist, on the levodopa-induced abnormal increase of lipid peroxidation (LPO) and caspase activities in 6-hydroxydopamine (6-OHDA)-lesioned mice. Daily treatments of levodopa/carbidopa for 7 days beginning at 1 day after 6-OHDA i.c.v. injection increased striatal DA levels and glutathione (GSH) contents. Furthermore, a high dose of levodopa/carbidopa (50/12.5 mg/kg) enhanced LPO and caspase-3, -8, and -9 activities in 6-OHDA-lesioned mouse brain. However, when levodopa/carbidopa (50/12.5 mg/kg) was combined with cabergoline (0.25 mg/kg), the effect reduced levodopa's enhancement of caspase-3, -8, and -9 activities in the 6-OHDA-lesioned mouse brain. In addition, the GSH-increasing effect of the combined cabergoline and levodopa/carbidopa treatment was stronger than that of the levodopa/carbidopa mono-treatment. Moreover, cabergoline prevented levodopa-induced abnormal increases of LPO in 6-OHDA-lesioned mice. These results indicate that such prevention is attributable mainly to the increase in GSH content and to the inhibition of caspase activities in 6-OHDA-lesioned mice.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.neures.2004.09.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Systemically circulating 17β-estradiol enhances the neuroprotective effect of the smoking cessation drug cytisine in female parkinsonian mice.
NPJ Parkinsons Dis
January 2025
Department of Neuroscience & Experimental Therapeutics, Texas A&M University College of Medicine, 8447 John Sharp Pkwy, Bryan, TX, 77807-3260, USA.
The smoking cessation drug cytisine exerts neuroprotection in substantia nigra pars compacta (SNc) dopaminergic (DA) neurons of female but not male 6-hydroxydopamine (6-OHDA) lesioned parkinsonian mice. To address the important question of whether circulating 17β-estradiol mediates this effect, we employ two mouse models aimed at depleting systemically circulating 17β-estradiol: (i) bilateral ovariectomy (OVX), and (ii) aromatase inhibition with systemically administered letrozole. In both models, depleting systemically circulating 17β-estradiol in female 6-OHDA lesioned parkinsonian mice results in the loss of cytisine-mediated neuroprotection as measured using apomorphine-induced contralateral rotations and SNc DA neurodegeneration.
View Article and Find Full Text PDFEnhancing striatal acetylcholine facilitates dopamine release and striatal output in parkinsonian mice.
Cell Biosci
December 2024
Department of Neurology & Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Background: L-DOPA has been considered the first-line therapy for treating Parkinson's disease (PD) via restoring striatal dopamine (DA) to normalize the activity of local spiny projection neurons (SPNs) in the direct (dSPNs) pathway and the indirect (iSPNs) pathway. While the changes in striatal acetylcholine (ACh) induced by increasing DA have been extensively discussed, their validity remains controversial. Inhibition of striatal cholinergic signaling attenuates PD motor deficits.
View Article and Find Full Text PDFEffects of puerarin on gait disturbance in a 6-hydroxydopamine mouse model of Parkinson's disease.
Pharmacol Rep
February 2025
Department of Food Science and Nutrition, Daegu Catholic University, 13-13 Hayang-Ro, Hayang-Eup, Gyeongsan, Gyeongbuk, 38430, Republic of Korea.
Background: Parkinson's disease (PD) is a neurodegenerative disorder caused by dopamine (DA) neuronal dysfunction. Although DA agonists and N-methyl-D-aspartate receptor (NMDAR) antagonists are used to treat PD, chronic use causes severe side effects. Puerarin (PUE) is a natural bioactive compound that affects the DA system; however, its effect on PD-associated motor functions is unknown.
View Article and Find Full Text PDFTransient Increases in Neural Oscillations and Motor Deficits in a Mouse Model of Parkinson's Disease.
Int J Mol Sci
September 2024
Key Laboratory of Southwest China Wildlife Resources Conservation (Ministry of Education), China West Normal University, Nanchong 637009, China.
Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor symptoms like tremors and bradykinesia. PD's pathology involves the aggregation of α-synuclein and loss of dopaminergic neurons, leading to altered neural oscillations in the cortico-basal ganglia-thalamic network. Despite extensive research, the relationship between the motor symptoms of PD and transient changes in brain oscillations before and after motor tasks in different brain regions remain unclear.
View Article and Find Full Text PDFCharacterization of D1R and D2R neuronal subpopulations in the globus pallidus interna: Implications for Parkinson's disease pathogenesis.
Brain Res
December 2024
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China. Electronic address:
Article Synopsis
- Parkinson's disease (PD) is a common brain disorder that causes problems with movement and is getting more prevalent.
- Scientists found important brain cells in a specific area called the globus pallidus interna (GPi) that behave differently in PD patients compared to healthy people.
- The study looked at two types of brain cells linked to dopamine (a chemical in the brain) and discovered that one type had unusual behaviors in mice with PD, which may help explain how the disease develops.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!